collection
MENU ▼
Read by QxMD icon Read
search

Renal Anemia

shared collection
108 papers 100 to 500 followers
By Isabel Acosta-Ochoa Nephrology senior staff. Valladolid. Spain
https://www.readbyqxmd.com/read/29779027/association-of-pre-end-stage-renal-disease-hemoglobin-with-early-dialysis-outcomes
#1
Carola-Ellen Kleine, Melissa Soohoo, Omesh N Ranasinghe, Christina Park, Maria V Marroquin, Yoshitsugu Obi, Connie M Rhee, Hamid Moradi, Csaba P Kovesdy, Kamyar Kalantar-Zadeh, Elani Streja
BACKGROUND: Incident hemodialysis patients have a high mortality risk within the first months after dialysis initiation. Pre-end-stage renal disease (ESRD) factors like anemia management may impact early post-ESRD outcomes. Therefore, we evaluated the impact of pre-ESRD hemoglobin (Hgb) and pre-ESRD Hgb slope on post-ESRD mortality and hospitalization outcomes. METHODS: The study included 31,472 veterans transitioning to ESRD. Using Cox and negative binomial regression models, we evaluated the association of pre-ESRD Hgb and Hgb slope with 12-month post-ESRD all-cause and cardiovascular mortality and hospitalization rates using 4 levels of hierarchical multivariable adjustment, including erythropoietin use and kidney decline in slope models...
May 18, 2018: American Journal of Nephrology
https://www.readbyqxmd.com/read/29767854/emerging-association-between-parathyroid-hormone-and-anemia-in-hemodialysis-patients
#2
REVIEW
Motoko Tanaka, Hirotaka Komaba, Masafumi Fukagawa
Anemia is a common complication of chronic kidney disease (CKD). There are various causes of renal anemia such as decreased production of erythropoietin, resistance to erythropoietin, shortened survival of red blood cells, and bone marrow fibrosis. Secondary hyperparathyroidism (SHPT) is a less recognized, but potentially significant cause of renal anemia in CKD patients. Parathyroid hormone (PTH) has been regarded as a uremic toxin that has multiple adverse effects, and its elevated levels have been associated with renal anemia in hemodialysis patients...
May 16, 2018: Therapeutic Apheresis and Dialysis
https://www.readbyqxmd.com/read/29744352/limitations-of-serum-ferritin-in-diagnosing-iron-deficiency-in-inflammatory-conditions
#3
REVIEW
Axel Dignass, Karima Farrag, Jürgen Stein
Patients with inflammatory conditions such as inflammatory bowel disease (IBD), chronic heart failure (CHF), and chronic kidney disease (CKD) have high rates of iron deficiency with adverse clinical consequences. Under normal circumstances, serum ferritin levels are a sensitive marker for iron status but ferritin is an acute-phase reactant that becomes elevated in response to inflammation, complicating the diagnosis. Proinflammatory cytokines also trigger an increase in hepcidin, which restricts uptake of dietary iron and promotes sequestration of iron by ferritin within storage sites...
2018: International Journal of Chronic Diseases
https://www.readbyqxmd.com/read/29734151/renal-anemia-and-iron-metabolism
#4
Chie Ogawa, Ken Tsuchiya, Kunimi Maeda, Kosaku Nitta
Normal iron metabolism is essential for effective hemoglobin (Hb) production in the management of renal anemia. Considering that studies regarding the optimal Hb levels predated the creation of the iron management indices found in the treatment guidelines for hemodialysis (HD) patients, an increase in the Hb levels caused by intravenous iron supplementation has been used as an iron management index. However, no consideration was given to iron metabolism or the long-term safety of intravenous iron supplementation...
2018: Contributions to Nephrology
https://www.readbyqxmd.com/read/29712435/prolyl-hydroxylase-inhibitors-a-breakthrough-in-the-therapy-of-anemia-associated-with-chronic-diseases
#5
Amit Arvind Joharapurkar, Vrajesh Bhaskarbhai Pandya, Vishal J Patel, Ranjit C Desai, Mukul R Jain
Chronic kidney disease, cancer, chronic inflammatory disorders, nutritional and genetic deficiency can cause anemia. Hypoxia causes induction of hypoxia-inducible factor (HIF), which stimulates erythropoietin (EPO) synthesis. Prolyl hydroxylase domain (PHD) enzyme inhibition can stabilize hypoxia-inducible factor (HIF). HIF stabilization also decreases hepcidin, a hormone of hepatic origin, which regulates iron homeostasis. PHD inhibitors represent the novel pharmacological treatment of anemia of chronic diseases...
May 1, 2018: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29680173/iron-deficiency-in-chronic-and-acute-heart-failure-a-contemporary-review-on-intertwined-conditions
#6
REVIEW
Gonçalo J L Cunha, Bruno M L Rocha, Luiz Menezes Falcão
Iron Deficiency (ID) is increasingly recognized as a prevalent comorbid condition in Heart Failure (HF). Despite this, the pathophysiological mechanisms for progressive ID in either chronic or acute HF are still poorly understood. Beyond the traditional factors for iron deficit in the general population, we ought to review the specificities of such paucity in the HF patient, particularly focusing on the interplay between heightened inflammation, overactivity of the sympathetic nervous system and the so-called cardio-renal-anaemia-ID syndrome...
April 18, 2018: European Journal of Internal Medicine
https://www.readbyqxmd.com/read/29666917/measurement-of-iron-status-in-chronic-kidney-disease
#7
Wesley Hayes
Anemia is a common complication of chronic kidney disease (CKD) in children, and dysregulation of iron homeostasis plays a central role in its pathogenesis. Optimizing iron status is a prerequisite for effective treatment of anemia. Insufficient iron can lead to inappropriate escalation of the erythropoiesis-stimulating agent (ESA) dose, which is associated with adverse outcomes. Excess iron supplementation also has negative sequelae including free radical tissue damage and increased risk of systemic infection...
April 17, 2018: Pediatric Nephrology: Journal of the International Pediatric Nephrology Association
https://www.readbyqxmd.com/read/29672740/effects-of-vadadustat-on-hemoglobin-concentrations-in-patients-receiving-hemodialysis-previously-treated-with-erythropoiesis-stimulating-agents
#8
Volker H Haase, Glenn M Chertow, Geoffrey A Block, Pablo E Pergola, Emil M deGoma, Zeeshan Khawaja, Amit Sharma, Bradley J Maroni, Peter A McCullough
Background: Vadadustat, an inhibitor of hypoxia-inducible factor prolyl-4-hydroxylase domain dioxygenases, is an oral investigational agent in development for the treatment of anemia secondary to chronic kidney disease. Methods: In this open-label Phase 2 trial, vadadustat was evaluated in 94 subjects receiving hemodialysis, previously maintained on epoetin alfa. Subjects were sequentially assigned to one of three vadadustat dose cohorts by starting dose: 300 mg once daily (QD), 450 mg QD or 450 mg thrice weekly (TIW)...
April 16, 2018: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/29655605/physiology-and-pathophysiology-of-renal-erythropoietin-producing-cells
#9
REVIEW
Hong-Mou Shih, Chih-Jen Wu, Shuei-Liong Lin
Anemia is a common complication and contributes to increased morbidity and mortality in chronic kidney disease (CKD) patients. Whereas there has been a significant improvement of understanding the underlying mechanism of erythropoiesis, the treatment of renal anemia is still restricted to erythropoietin (EPO)-stimulating agents. The purpose of this article is to review the physiology of erythropoiesis, functional role of EPO and underlying molecular and cellular basis that regulate EPO production. Regulation of EPO production is at mRNA level...
April 11, 2018: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/29463398/quel-pourrait-%C3%A3%C2%AAtre-le-futur-de-la-prise-en-charge-de-l%C3%A2-an%C3%A3-mie-dans-l%C3%A2-insuffisance-r%C3%A3-nale-chronique
#10
O Hermine, Th Maciel, I Moura
Erythropoietin (EPO) plays an essential role in the regulation of erythropoiesis. Its production is under the control of the Hypoxia Inducible Factor (HIF) protein whose stability varies according to the oxygen level. During chronic renal failure, EPO deficiency is the main cause of anemia, but other factors such as iron deficiency and inflammatory syndrome are also involved. More recently, it is hypothesized that other factors such an excess of GDF-11 production may be also involved. Thus, beside Epo treatment HIF and GDF-11 are potentially new therapeutic targets in anemia of chronic kidney disease...
June 2017: Néphrologie & Thérapeutique
https://www.readbyqxmd.com/read/29382128/hypoxia-inducible-factor-and-its-role-in-the-management-of-anemia-in-chronic-kidney-disease
#11
REVIEW
Joshua M Kaplan, Neeraj Sharma, Sean Dikdan
Hypoxia-inducible factor (HIF) plays a crucial role in the response to hypoxia at the cellular, tissue, and organism level. New agents under development to pharmacologically manipulate HIF may provide new and exciting possibilities in the treatment of anemia of chronic kidney disease (CKD) as well as in multiple other disease states involving ischemia-reperfusion injury. This article provides an overview of recent studies describing current standards of care for patients with anemia in CKD and associated clinical issues, and those supporting the clinical potential for targeting HIF stabilization with HIF prolyl-hydroxylase inhibitors (HIF-PHI) in these patients...
January 29, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29357391/iron-deficiency-across-chronic-kidney-disease-stages-is-there-a-reverse-gender-pattern
#12
Mabel Aoun, Rita Karam, Ghassan Sleilaty, Leony Antoun, Walid Ammar
In non-dialysis chronic kidney disease patients, looking for iron deficiency is highly variable in practice and there is a great variability regarding the cutoffs used to treat iron deficiency. The aim of this study is to investigate the degree of iron deficiency in non-dialysis chronic kidney disease patients on erythropoiesis-stimulating agents. We included all non-dialysis chronic kidney disease patients that applied to the Lebanese Ministry of Public Health for erythropoiesis-stimulating agents' coverage during a 5-month period...
2018: PloS One
https://www.readbyqxmd.com/read/29254377/roxadustat-in-the-treatment-of-anaemia-in-chronic-kidney-disease
#13
Lucia Del Vecchio, Francesco Locatelli
Anaemia is one of the hallmarks of advanced chronic kidney disease (CKD); it correlates with a lower quality of life and increased cardiovascular risk. Currently its management is based on iron and erythropoiesis-stimulating agents (ESAs) therapy. Given safety issues on ESA therapy and excessive iron use, anaemia management is still suboptimal. Areas covered: The inhibitors of the prolyl-hydroxylases domain (PHD) are oral drugs which activate the hypoxia-inducible factors (HIF) and stimulate the production of endogenous erythropoietin...
January 2018: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/29250136/%C3%AE-klotho-and-anemia-in-patients-with-chronic-kidney-disease-patients-a-new-perspective
#14
Yang Xu, Hao Peng, Ben Ke
Normocytic normochromic anemia is a common complication of chronic kidney disease (CKD) and is associated with numerous adverse consequences. Certain symptoms previously attributed to CKD are now known to be a consequence of anemia. Anemia contributes to an increased cardiac output, and the development of left ventricular hypertrophy, angina and congestive heart failure, leading to high morbidity and mortality in patients with CKD. The multifunctional α-klotho (KL) protein, which is predominantly expressed in the kidneys, is associated with the occurrence of anemia in patients with CKD...
December 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/29227972/serum-hepcidin-and-iron-indices-affect-anemia-status-differently-according-to-the-kidney-function-of-non-dialysis-chronic-kidney-disease-patients-korean-cohort-study-for-outcome-in-patients-with-chronic-kidney-disease-know-ckd
#15
Sung Woo Lee, Yeong Hoon Kim, Wookyung Chung, Sue K Park, Dong Wan Chae, Curie Ahn, Yong-Soo Kim, Su Ah Sung
BACKGROUND/AIMS: No studies have examined the association among serum hepcidin, iron indices, or anemia status based on the kidney function of non-dialysis chronic kidney disease (CKD) patients. METHODS: We reviewed data of 2238 patients from a large-scale multicenter prospective Korean study (2011-2016) and excluded 198 patients with missing data regarding serum hepcidin, hemoglobin, transferrin saturation (TSAT), ferritin, and usage of erythropoiesis-stimulating agents (ESA) or supplemental iron and 363 patients using ESA or supplemental iron...
2017: Kidney & Blood Pressure Research
https://www.readbyqxmd.com/read/29153343/prevalence-of-anemia-in-hospitalized-internal-medicine-patients-correlations-with-comorbidities-and-length-of-hospital-stay
#16
Carlo Zaninetti, Catherine Klersy, Concetta Scavariello, Raffaella Bastia, Carlo L Balduini, Rosangela Invernizzi
BACKGROUND: Several studies have documented a linear growth of the prevalence of anemia with aging. Especially in hospitalized elderly patients, anemia can aggravate the course of chronic disorders, and ultimately get worse the clinical outcomes. METHODS: To evaluate the distribution, the main causes, and the possible correlations of anemia with comorbidities and length of hospitalization in a population of internal medicine inpatients, we carried out an observational study on a cohort of 923 consecutive admissions relative to 856 subjects...
November 16, 2017: European Journal of Internal Medicine
https://www.readbyqxmd.com/read/29128260/anemia-of-chronic-kidney-disease-protocol-of-study-management-and-referral-to-nephrology
#17
Aleix Cases, M Isabel Egocheaga, Salvador Tranche, Vicente Pallarés, Raquel Ojeda, José Luis Górriz, José María Portolés
The objective of this protocol is to know which test are needed to study an anaemia in a patient with chronic kidney disease, the differential diagnosis of renal anaemia, to know and correct other deficiency anaemias, and the criteria for referral to Nephrology or other specialties of the anaemic patient with chronic kidney disease.
January 2018: Nefrología: Publicación Oficial de la Sociedad Española Nefrologia
https://www.readbyqxmd.com/read/28745688/-risk-factors-for-anemia-in-the-early-stages-of-chronic-kidney-disease
#18
Yu S Milovanov, L V Kozlovskaya, L Yu Milovanova, M M Markina, V V Kozlov, M V Taranova, V V Fomin
AIM: To identify the early markers of anemia in chronic kidney disease (CKD) in patients with chronic glomerulonephritis (CGN) and glomerulonephritis (GN) in systemic diseases. SUBJECTS AND METHODS: Seventy-nine patients with some male preponderance who were aged 21 to 65 years (45.3±11.1 years) and had CKD (CGN and GN) in systemic diseases (systemic lupus erythematosus and Wegener's granulomatosis) in the early stages (Stages I-II) of CKD were examined. GN was diagnosed by a lifetime renal biopsy...
2017: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/28682026/-clinical-management-of-anemia-in-patients-with-ckd
#19
Rodolfo Fernando Rivera, Maria Teresa Sciarrone Alibrandi, Luca Di Lullo, Fulvio Fioccari
Anemia is a frequent complication in chronic kidney disease (CKD), and it is often accompanied by various clinical symptoms. The primary cause of anemia in CKD patients is the reduction in the erythropoietin production, which results in a decrease of signaling molecule that stimulates red blood cell production. Other possible causes of anemia in CKD include iron deficiency, inflammation, and the accumulation of uremic toxin. This chapter focuses the discussion on the strategy of the management of anemia in patients with CKD...
March 2017: Giornale Italiano di Nefrologia: Organo Ufficiale Della Società Italiana di Nefrologia
https://www.readbyqxmd.com/read/28457030/evaluation-of-effect-of-vitamin-d-deficiency-on-anemia-and-erythropoietin-hyporesponsiveness-in-patients-of-chronic-kidney-disease
#20
N Nand, R Mittal
BACKGROUND: The role of vitamin D deficiency and inflammation levels in renal anemia has been documented. However, no study is available in India where the role of vitamin D supplementation in patients with hyporesponsiveness to increased doses of erythropoietin is available. Hence this study. MATERIAL AND METHODS: This study was conducted on 50 adult patients of CKD, on regular, twice weekly hemodialysis. It included 38 cases in group A with deficient serum vitamin D levels (<30 ng/ml) and 12 cases in group B with sufficient vitamin D levels (>30 ng/ml)...
February 2017: Journal of the Association of Physicians of India
label_collection
label_collection
1756
1
2
2018-04-17 07:20:20
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"